Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, Liesveld JL, Brookes PS, Becker MW, Jordan CT.

Cell Stem Cell. 2013 Mar 7;12(3):329-41. doi: 10.1016/j.stem.2012.12.013. Epub 2013 Jan 17.

2.

BCL-2 inhibition: stemming the tide of myeloid malignancies.

Hogdal LJ, Letai A.

Cell Stem Cell. 2013 Mar 7;12(3):269-70. doi: 10.1016/j.stem.2013.02.006.

4.

Mechanisms of anti-leukemic activity of the Bcl-2 homology domain-3 mimetic S1.

Liu Y, Li Z, Song T, Xue Z, Zhang Z.

Biomed Pharmacother. 2013 Sep;67(7):583-91. doi: 10.1016/j.biopha.2013.04.010. Epub 2013 May 3.

PMID:
23706691
5.

Lower phosphorylation of p38 MAPK blocks the oxidative stress-induced senescence in myeloid leukemic CD34(+)CD38 (-) cells.

Xiao Y, Zou P, Wang J, Song H, Zou J, Liu L.

J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):328-33. doi: 10.1007/s11596-012-0057-z. Epub 2012 Jun 9.

PMID:
22684553
7.

Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

Bruedigam C, Bagger FO, Heidel FH, Paine Kuhn C, Guignes S, Song A, Austin R, Vu T, Lee E, Riyat S, Moore AS, Lock RB, Bullinger L, Hill GR, Armstrong SA, Williams DA, Lane SW.

Cell Stem Cell. 2014 Dec 4;15(6):775-90. doi: 10.1016/j.stem.2014.11.010.

8.

Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species.

Zhou J, Li P, Xue X, He S, Kuang Y, Zhao H, Chen S, Zhi Q, Guo X.

Toxicol Lett. 2013 Oct 24;222(2):139-45. doi: 10.1016/j.toxlet.2013.07.022. Epub 2013 Aug 2.

9.

The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.

Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT.

Blood. 2005 Jun 1;105(11):4163-9. Epub 2005 Feb 1.

10.
11.

Preferential eradication of acute myelogenous leukemia stem cells by fenretinide.

Zhang H, Mi JQ, Fang H, Wang Z, Wang C, Wu L, Zhang B, Minden M, Yang WT, Wang HW, Li JM, Xi XD, Chen SJ, Zhang J, Chen Z, Wang KK.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5606-11. doi: 10.1073/pnas.1302352110. Epub 2013 Mar 19.

12.

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA, Jordan CT.

Blood. 2007 Dec 15;110(13):4427-35. Epub 2007 Sep 5.

13.

Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.

Hong Z, Xiao M, Yang Y, Han Z, Cao Y, Li C, Wu Y, Gong Q, Zhou X, Xu D, Meng L, Ma D, Zhou J.

Carcinogenesis. 2011 Oct;32(10):1550-8. doi: 10.1093/carcin/bgr176. Epub 2011 Jul 29.

PMID:
21803735
14.

In vivo selective imaging and inhibition of leukemia stem-like cells using the fluorescent carbocyanine derivative, DiOC5(3).

Zhang B, Shimada Y, Kuroyanagi J, Ariyoshi M, Nomoto T, Shintou T, Umemoto N, Nishimura Y, Miyazaki T, Tanaka T.

Biomaterials. 2015 Jun;52:14-25. doi: 10.1016/j.biomaterials.2015.02.009. Epub 2015 Feb 21.

PMID:
25818410
15.

Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.

Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M.

Blood. 2002 May 1;99(9):3461-4.

16.

Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.

Cook AM, Li L, Ho Y, Lin A, Li L, Stein A, Forman S, Perrotti D, Jove R, Bhatia R.

Blood. 2014 May 1;123(18):2826-37. doi: 10.1182/blood-2013-05-505735. Epub 2014 Mar 25.

17.

Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.

Kim YR, Eom JI, Kim SJ, Jeung HK, Cheong JW, Kim JS, Min YH.

J Pharmacol Exp Ther. 2010 Nov;335(2):389-400. doi: 10.1124/jpet.110.169367. Epub 2010 Aug 10.

18.

OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis.

Bai LY, Weng JR, Chiu CF, Wu CY, Yeh SP, Sargeant AM, Lin PH, Liao YM.

Biochem Pharmacol. 2013 Nov 15;86(10):1430-40. doi: 10.1016/j.bcp.2013.09.002. Epub 2013 Sep 13.

PMID:
24041743
19.

Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.

Xiong XX, Liu JM, Qiu XY, Pan F, Yu SB, Chen XQ.

Acta Pharmacol Sin. 2015 Mar;36(3):362-74. doi: 10.1038/aps.2014.141. Epub 2015 Jan 26.

20.

Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.

Bosman MC, Schuringa JJ, Quax WJ, Vellenga E.

Exp Hematol. 2013 Jun;41(6):530-538.e1. doi: 10.1016/j.exphem.2013.02.002. Epub 2013 Feb 13.

PMID:
23416210

Supplemental Content

Support Center